How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about nirmatrelvir plus ritonavir

Marketing authorisation indication

2.1 Nirmatrelvir plus ritonavir (Paxlovid, Pfizer) is 'indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19'.

Dosage in the marketing authorisation

2.2 The dosage schedule for nirmatrelvir plus ritonavir is available in the summary of product characteristics for nirmatrelvir plus ritonavir.

Price

2.3 The list price for nirmatrelvir plus ritonavir is £829 for a 20‑pack of 150‑mg nirmatrelvir tablets and a 10‑pack of 100‑mg ritonavir tablets (excluding VAT; MIMS online, accessed October 2022). Costs may vary in different settings because of negotiated procurement discounts.